Tag Archives: Innovator’s Pitch Challenge

Calling All Life Science Entrepreneurs – Enter the RESI Boston Innovation Challenge

13 Jul

By Chris Cummings, Senior Business Development Manager, LSN

Christine A. Wu, Senior Research Analyst, LSN

chrsitineRESI is coming home to Boston and so is the RESI Innovation Challenge. This September’s life science innovation competition will showcase the most promising new health technologies in the RESI Innovation Challenge. If you are fundraising and aim to build a presence in the Boston’s booming healthcare scene, we’d like to see your application.

The RESI Innovation Challenge invites the top-tier early-stage companies in therapeutics, medical devices, diagnostics and healthcare IT to present from around the globe. All applicants will be vetted on the crucial balance of the quality of the company’s scientific innovation and the investment potential based on the company current standings and management team.

On September 26th, RESI’s estimated 1000 attendees will receive “RESI Cash” to “invest” in the company whom they believe to be the most “investible” of the contestants. The top three winners with the most RESI cash will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

In the past we have seen around 50% of Innovation Challenge companies receive funding within a year from their exhibition at RESI. Be sure not to miss out on the chance of adding to this statistic – apply for the Innovation Challenge.

See below for the previous RESI Innovation Challenge testimonials.

“RESI Innovation Challenge was a fantastic way for us to increase exposure to investors attending the event. We highly recommend leveraging the Innovation Challenge with the one-on-one partnering platform to get more face time with investors.”

– Herman Lo, CEO, ViewsIQ Inc.

3rd Place in San Diego IC

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

RESI San Diego 2017 Innovation Challenge – Winners Announced

22 Jun

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

RESI Innovation Challenge: LSN’s Scientific Review Team Selects 30 Top Life Science Startups

1 Jun

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

We are pleased to announce our thirty finalists to compete in the Innovation Challenge at Life Science Nation’s (LSN) first-ever RESI in San Diego. From a pool of approximately 100 applicants, the LSN Scientific Review Team has selected a diverse group of life science startups: three healthcare IT, three diagnostic, thirteen therapeutic, and eleven medical device companies.  These startups will showcase themselves in the exhibit hall display spaces at RESI on June 19th. The quality of these companies should not go unnoticed, as we have seen nearly 50% of Innovation Challenge finalists from previous RESI’s receive funding within one year of their debut.

From personalized cancer immunotherapies to digital pathology imaging, these companies cover a diverse range of life science technologies. Coming from all over the world, the companies will be competing based on scientific merit and investment potential, pitching to RESI attendees and showcasing their innovations. Be sure to catch them and make your “investments” at the RESI Exhibition Hall in just a couple weeks!

Therapeutic
 
Diagnostic
Medical Device
 
Healthcare IT
 

Get Your Startup in the Spotlight at the RESI Innovation Challenge in San Diego

20 Apr

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

RESI is going to BIO. As we join 2017’s largest life science innovation carnival, we aim to showcase the most promising, innovative new health technologies in the RESI Innovation Challenge. If you’re headed to San Diego with the aim of raising money or making deals for your startup, we’d like to see your application.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On June 19th, RESI’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder, Steadiwear | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

RESI on MaRS 2017 Innovation Challenge 1st Place Winner – Steadiwear inc.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

APPLICATION DEADLINE: May 5, 2017

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 

– Raymond Shih, President, Co-Founder, QoC Health

3rd Place, RESI on MaRS, June 23, 2016

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

RESI on MaRS Innovation Challenge – Winners Announced

6 Apr

By Nono Hu, Director of Marketing, LSN

On April 4, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Steadiwear

Steadiwear inc.‘s mission is to restore independence and quality of life to all tremor sufferers worldwide. We have developed the Steadiglove, a smart glove that responsively stabilizes hand tremors in Essential Tremor and Parkinson’s disease using novel vibration damping technology. This allows users to go about all daily activities such as eating and getting dressed with significantly less frustration.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Second Place: BlueLight

BlueLight is a healthcare technology company specializing in the measurement of light energy. Our data-driven technologies, sold worldwide, target a quality gap in the multi billion-dollar dental composite market.

Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation | Michael Quigley, VP of Market Research, Life Science Nation | JP Furey, CEO, BlueLight | Peter MacLareN, Director of Customer Relations, BlueLight

Third Place: Cyclica

Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.

Michael Quigley, VP of Market Research, Life Science Nation | Naheed Kurji, President and CEO, Cyclica | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Thank you to all who competed in the RESI on MaRS Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

30 Leading Life Science Startups Compete in Innovation Challenge at The Redefining Early Stage Investments (RESI) Conference at MaRS

9 Mar

By Michael Quigley, VP of Market Research, LSN

mike-2

As RESI gears up for its second landing on MaRs in Toronto this April 4th we are proud to announce our latest batch of life science/health tech companies that will be participating in the RESI Innovation Challenge.

30 companies from across North America, hand selected by LSN’s scientific and commercial review team, will compete directly on merits of innovation and commercial viability.  Past RESI events have seen as many as 50% of innovation challenge contestants go on to receive funding or significant partnerships within a year from the competition.

From companies helping to detect oncoming seizures to those developing cost effective ways of growing blood stem cells, this diverse class of competitors is sure to impress. Come check them our yourself in the Exhibition Hall at RESI on MaRs on April 4th!

Therapeutic
 
Diagnostic
Medical Device
 
Healthcare IT
 

RESI on MaRS – Spotlight Your Technology in the RESI Innovation Challenge

2 Feb

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

LSN is gearing up for the upcoming Redefining Early Stage Investments (RESI) Conference in Toronto’s MaRS Discovery District, and we’re seeking fundraising CEOs with the most promising early stage healthcare technologies to showcase in the RESI Innovation Challenge on April 4, 2017.

LSN’s scientific team is preparing to review the RESI Innovation Challenge applications from therapeutics, medtech, diagnostics and healthcare IT companies around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On April 4, 2017, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

apply-button

APPLICATION DEADLINE: FEB. 15, 2017

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

“I love the RESI Innovation Challenge because it is a great way to give our pitch to practice it and try to obtain a scarce resource from these investors. Practicing with these investors is a great way to build relationships and continue that on to the real investment conversations.”

– Niko Skievaski, Co-Founder, Redox

1st Place, RESI@TMCx, June 8, 2015

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

01

“RESI offers small companies like GeneSegues a direct line to potential partners and potential investors in a small setting conducive to relationship building and conversation. The Innovation Challenge was a particularly great way to introduce our company to a broader audience than I could meet with personally which allowed us to leverage the showcasing of our technology more efficiently.”

-Laura M. Brod,Chief Executive Officer,GeneSegues Therapeutics

-1st Place, RESI @TMCx, April 11, 2016